Borderline resectable pancreas adenocarcinoma managed with neoadjuvant chemoradiotherapy: A prospective case series.

被引：0
|
作者：
Mandaliya, Hiren A.
Martin, Jarad
Majid, Adeeb
Gani, Jon
Sridharan, Swetha
Ackland, Stephen P.
Kumar, Mahesh
Shah, Kalpesh
Chen, Stanley
Fay, Michael
Lynam, James F.
Van Der Westhuizen, Andre
Mallesara, Girish
Philcox, Stephen
Bonaventura, Tony
Day, Fiona
机构：
[1] Calvary Mater Hosp, Newcastle, NSW, Australia
[2] Calvary Mater Newcastle, Newcastle, NSW, Australia
[3] John Hunter Hosp, Newcastle, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.499
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
499
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas
    Wolff, Robert A.
    [J]. CURRENT DRUG TARGETS, 2012, 13 (06) : 781 - 788
  • [2] Neoadjuvant FOLFIRINOX in borderline resectable adenocarcinoma of the pancreas-5 year suvival data of a consecutive case series
    Tinchon, C.
    Pichler, A.
    Mayer, D.
    Lammer, M.
    Reisinger, A.
    Rabl, H.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 304 - 304
  • [3] Neoadjuvant treatment concepts for borderline-resectable adenocarcinoma of the pancreas
    MSc, S. Roth
    Mba, M. Schneider
    [J]. CHIRURGIE, 2022, 93 (10): : 995 - 996
  • [4] Neoadjuvant Chemoradiotherapy for Resectable and Borderline Resectable Pancreatic Cancer
    Attaallah, Wafi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 3346 - +
  • [5] Pathologic Response to Neoadjuvant Chemotherapy and Chemoradiation in Borderline Resectable Adenocarcinoma of the Pancreas
    Lee, Joon K.
    Ghanem, Ahmed I.
    Burmeister, Charlotte
    Jaratli, Hayan
    Raoufi, Mohammad
    Khan, Gazala
    Dobrosotskaya, Irina
    Kwon, David
    Siddiqui, Farzan
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (02): : E4 - E4
  • [6] Neoadjuvant Chemoradiotherapy for Resectable and Borderline Resectable Pancreatic Cancer
    Hayakawa, S.
    Karasawa, K.
    Fujisawa, T.
    Ito, K.
    Shibata, Y.
    Shimizuguchi, T.
    Nihei, K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E236 - E236
  • [7] Predictors of Undergoing Surgical Resection after Neoadjuvant Chemoradiotherapy for Borderline Resectable and Resectable Pancreatic Adenocarcinoma
    Neibart, S. S.
    Mamidanna, S.
    Chundury, A.
    Sayan, M.
    Alexander, H. R.
    August, D.
    Berim, L. D.
    Boland, P. M.
    Grandhi, M. S.
    Gulhati, P.
    Kennedy, T. J.
    Langan, R. C.
    Spencer, K.
    Jabbour, S. K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E63 - E64
  • [8] Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Homma, Yuki
    Taniguchi, Koichi
    Murakami, Takashi
    Nakagawa, Kazuya
    Nakazawa, Masatoshi
    Matsuyama, Ryusei
    Mori, Ryutaro
    Takeda, Kazuhisa
    Ueda, Michio
    Ichikawa, Yasushi
    Tanaka, Kuniya
    Endo, Itaru
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (02) : 670 - 676
  • [9] Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Yuki Homma
    Koichi Taniguchi
    Takashi Murakami
    Kazuya Nakagawa
    Masatoshi Nakazawa
    Ryusei Matsuyama
    Ryutaro Mori
    Kazuhisa Takeda
    Michio Ueda
    Yasushi Ichikawa
    Kuniya Tanaka
    Itaru Endo
    [J]. Annals of Surgical Oncology, 2014, 21 : 670 - 676
  • [10] Intraoperative radiotherapy (IORT) in the era of intensive neoadjuvant chemotherapy and chemoradiotherapy for locally advanced and borderline resectable adenocarcinoma of the pancreas (PDAC).
    Keane, Florence K.
    Wo, Jennifer Yon-Li
    Ferrone, Cristina
    Clark, Jeffrey W.
    Blaszkowsky, Lawrence Scott
    Allen, Jill N.
    Kwak, Eunice Lee
    Ryan, David P.
    Lillemoe, Keith D.
    Fernandez-del Castillo, Carlos
    Hong, Theodore S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345